Advances in Ion-Exchange Chromatography Leading to Increased Efficiencies and Reduced Costs
New ion-exchange chromatography media are more tolerant of varying conditions, making it possible to eliminate process steps.
Ion-exchange chromatography is often a crucial component of the downstream processing of biopharmaceuticals. Innovative new exchangers with new ligand chemistries are making it possible to increase selectivity and capacity. Some also are tolerant of high salt conditions, enabling the elimination of some preparative steps. Jim Powell, business development manager with Asahi Kasei Bioprocess, Estelle Zelter, global product manager of ion-exchange chromatography at EMD Millipore, and Sylvio Bengio, head of scientific communications for the global chromatography group at Pall Life Sciences, spoke with Cynthia Challener, editor of the Pharmaceutical Sciences, Manufacturing & Marketplace Report, about recent developments in ion-exchange chromatography technology that are benefiting their pharmaceutical customers.
Capacity and selectivity are key
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
